VRDN Q1 2024 Earnings Call Summary

1. Key Financial Results and Metrics

Cash Position: Viridian Therapeutics ended Q1 2024 with $613 million in cash, cash equivalents, and short-term investments, providing a runway into the second half of 2026.

2. Strategic Updates and Business Highlights

Pipeline Progress:
- 001 IV Program: Enrollment for the Phase III THRIVE trial in patients with active Thyroid Eye Disease (TED) completed in March 2024, exceeding the target with 113 patients. Top-line results are expected in September 2024.
- 003 Subcutaneous Program: A positive Type C meeting with the FDA was completed, with plans to initiate pivotal trials mid-year 2024.
- FcRn Portfolio: The company aims to file an Investigational New Drug (IND) application for 006 by the end of 2024 and plans to present nonhuman primate data for 008 in the second half of 2024.
Market Opportunity: The TED market is significant, with an estimated 190,000 patients in the U.S. alone. The current standard of care has limitations, presenting an opportunity for Viridian’s differentiated therapies.

3. Forward Guidance and Outlook

BLA Filing: Viridian anticipates filing a Biologics License Application (BLA) for the 001 program in the second half of 2025, contingent on the completion of THRIVE 2 and safety data from the STRIVE study.
Clinical Trials: The company is on track to initiate pivotal trials for the 003 program and expects to provide updates on trial designs soon.

4. Bad News, Challenges, or Points of Concern

Competitive Landscape: There are concerns about competition in the TED market, particularly from existing therapies like TEPEZZA, which has seen declining sales. However, Viridian believes there is still significant unmet need and room for growth.
Safety Profile: Questions were raised regarding the safety profile of 001, particularly concerning hearing impairment, which has been a concern with existing therapies. The company is implementing measures to monitor and report adverse events rigorously.
Regulatory Risks: The timeline for the BLA submission is dependent on the completion of ongoing trials and the collection of sufficient safety data, which introduces uncertainty.

5. Notable Q&A Insights

Efficacy Expectations: Management indicated that achieving efficacy results similar to TEPEZZA would be considered a success for the THRIVE trial.
Safety Monitoring: The company is adopting rigorous safety monitoring practices, including audiometry assessments, to address concerns about hearing loss associated with TED treatments.
Enrollment Strategy: Strong demand was noted in the THRIVE trial, with management expressing confidence in the ability to attract patients due to the unmet needs in the TED market.
Future Studies: The potential for a combination of IGF-1R and FcRn therapies in TED was dismissed, with management focusing on IGF-1R as the key target for this condition.

Overall, Viridian Therapeutics is making significant strides in its clinical programs while navigating competitive pressures and regulatory challenges. The company remains optimistic about its growth prospects in the TED market and its broader pipeline.

VRDN — Viridian Therapeutics, Inc.